Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
NVP019
- Development stage
- Preclinical
- Lead developer
- NeuroVive
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
**NVP019** is a next-generation cyclophilin inhibitor derived from a novel chemistry platform, designed to be more potent, specific, and effective at lower doses than cyclosporine. It inhibits mitochondrial permeability transition pore (MPTP) opening, providing mitochondrial protection with applications in organ protection, reperfusion injury (e.g., myocardial infarction), traumatic brain injury, and various brain damages. Developed by NeuroVive Pharmaceutical (now Abliva) as an intravenous formulation for lifecycle management following CicloMulsion and NeuroSTAT, it was planned for Phase 1 trials around 2017; an oral formulation (NVP018) targeted antiviral indications including hepatitis B, hepatitis C, and HIV-1.
- Other names
- NVP018NVP-018NVP 018
02
Targets
PPIF (Cyclophilin D)MPTP (Mitochondrial permeability transition pore)PPIA (Peptidyl-prolyl cis-trans isomerase A)
Beyond the preview
Go deeper on NVP019.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NVP019.